Usgi Medical

USGI Medical is committed to the development of technologies that enable incisionless procedures which help patients return to normal activities and lifestyles faster compared to traditional laparoscopic and open surgery. We strive to eliminate the barriers to surgery by developing innovative and purposeful endoluminal technologies that make treatments less invasive, enable quicker recovery, and reduce overall cost. We commit to partnering with healthcare providers to offer incisionless solutions that improve the lives of patients worldwide. In the United States, USGI Medical's devices have been cleared by the FDA for approximation of soft tissue in minimally invasive gastroenterology procedures. The use of USGI's devices to treat obesity (including the POSE2.0 procedure) is currently under FDA investigation. USGI Medical also has CE Mark Indication for the use of its devices to treat obesity in patients with a BMI of 30-40.